Grant: Project Grant
University of British Columbia
$699,380.00
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
EF 2019-20
Résumé
While systemic therapy, such as chemotherapy, has been the mainstay of treatment for metastatic cancer (i.e. cancer that has spread to distant organs such as lung, liver, brain, or bone), there is emerging evidence that ablative treatment (e.g. surgery or radiotherapy) may extend life. This trial will randomize patients between receiving ablative radiotherapy versus receiving standard of care. The outcome of this trial will be important for future therapy decisions, and has the potential to change a treatment paradigm, and save health care dollars.
Programme
Project Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
409329
Name
Olson Robert A
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Randomized Controlled Trials
Projecttitle
A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$699,380
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biomarkers; Cost-Effectiveness/Cost-Utility; Metastatic Cancers; Oligometastatic Disease/State; Overall Survival; Progression-Free Survival; Quality Of Life; Quality-Adjusted Life Years; Stereotactic Radiotherapy; Toxicity
Abstract
While systemic therapy, such as chemotherapy, has been the mainstay of treatment for metastatic cancer (i.e. cancer that has spread to distant organs such as lung, liver, brain, or bone), there is emerging evidence that ablative treatment (e.g. surgery or radiotherapy) may extend life. This trial will randomize patients between receiving ablative radiotherapy versus receiving standard of care. The outcome of this trial will be important for future therapy decisions, and has the potential to change a treatment paradigm, and save health care dollars.
Competitiondate
201909
Approvedterm2
6 yrs 0 mth
Pinamesdelim
Olson, Robert A; Allan, Alison L; Palma, David; Peacock, Stuart J; Tyldesley, Scott K
Approvedterm
6 ans 0 mois
Cihrcontribution2
~ $699,380~ $0~
